Research on the Adjustment of Patent Protection Standards under Emergencies: Based on the TRIPs Agreement
DOI:
https://doi.org/10.54097/ehss.v1i.657Keywords:
Vaccines, Patents, TRIPs, Flexibility.Abstract
The patent system has a catalytic effect on innovation and imports, which could go some way to alleviating the current vaccine dilemma in the pandemic environment, i.e. insufficient capacity and inequitable distribution. This paper identifies this role through a review of the patent system and the TRIPs Agreement and argues that countries have the flexibility to adapt their patent systems to the current situation through the flexibility provisions of the TRIPs Agreement to maximize this facilitative role in addressing the vaccine issue. This paper suggests that in the current pandemic environment it is necessary to stimulate pharmaceutical companies to accelerate the process of vaccine development by reducing the inventive step testing requirements. In addition, to reduce market risk and maximize the extent to which patents can facilitate the vaccine development process, this paper argues that flexibility should not be used as an excuse for adjusting the duration of protection and requiring a complete patent waiver.
Downloads
References
World health organization, Weekly Epidemiological Update on COVID-19 , 2022-04-12, Retrieved April 15 2022, from https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---12-april-2022.
I. Caminschi, A. M. Lew, Vaccines, Current Opinion in Immunology, vol. 25, no. 3, 2013, pp. 356–358. https://doi.org/10.1016/j.coi.2013.05.008
M. Hosseini, A Covid Competition Dilemma: Legal and Ethical Challenges Regarding the Covid-19 Vaccine Policies during and after the Crisis, Public Governance, Administration and Finances Law Review, vol. 6, no. 1, 2021, pp. 51–63. https://doi.org/10.53116/pgaflr.2021.1.5
T. Chaudhary, A. Chaudhary, TRIPS waiver of COVID-19 vaccines: Impact on pharmaceutical industry and what it means to developing countries, The Journal of World Intellectual Property, vol. 24, no. 5-6, 2021, pp. 447–454. https://doi.org/10.1111/jwip.12198
G. H. Pike, Countries Seek IP Waiver for COVID Vaccines, Information Today, vol. 38, no. 6, 2021, pp. 24.
C. Kilpatrick, COVID: pharma says IP waivers won’t boost vaccine access, Managing Intellectual Property, 2020-11-05.
K. Olson, IP attorneys doubt patent waivers solution to global need for COVID vaccine, Massachusetts Lawyers Weekly, 2021-05-13.
L. Lessig, The future of ideas : the fate of the commons in a connected world, Vintage, 2002.
D. Guellec, B. Pottelsberghe de la Potterie, The Economics of the European Patent System IP Policy for Innovation and Competition, Oxford University Press, 2007.
O. Gurgula, Monopoly V. Openness: Two Sides of IP Coin in the Pharmaceutical Industry, The Journal of World Intellectual Property, vol. 20, no. 5-6, 2017, pp. 206–220. https://doi.org/10.1111/jwip.12081
F. M. Birhanu, Ethiopia’s World Trade Organization Accession and Maintaining Policy Space in Intellectual Property Policy in the Agreement on Trade-Related Aspects of Intellectual Property Rights Era: A Preliminary Look at the Ethiopian Patent Regime in the Light of the Agreement on Trade-Related Aspects of Intellectual Property Rights Obligations and Flexibilities, The Journal of World Intellectual Property, vol. 15, no. 3, 2012, pp. 171–198. https://doi.org/10.1111/j.1747-1796.2012.00437.x
R. E. Looney, Handbook of International Trade Agreements : Country, regional and global approaches, Routledge, 2018.
C. Deere-Birkbeck, The implementation game the TRIPS agreement and the global politics of intellectual property reform in developing countries, Oxford University Press, 2009.
F. Orsi, C. D’Almeida, L. Hasenclever, M. Camara, P. Tiger, B. Coriat, TRIPS post-2005 and access to new antiretroviral treatments in southern countries : issues and challenges, AIDS (London), vol. 21, no. 15, 2007, pp.1997-2003. https://doi.org/10.1097/QAD.0b013e328273bbe4
G. Mengistie, The impact of the international patent system on developing countries, Journal of Ethiopian Law, vol. 23, no. 1, 2009, pp. 161-219.
J. Potts, Q: Is intellectual property a government-granted monopoly, Review (Institute of Public Affairs (Australia) : 1997), vol. 64, no. 4, 2012, pp. 46-47.
I. Elangi Botoy, Potential and substantial benefits of the TRIPS Agreement to the member countries of the African Intellectual Property Organization in the patent field: an African’s perspective, The Journal of World Intellectual Property, vol. 4, no.1, 2001, pp. 91–103. https://doi.org/10.1111/j.1747-1796.2001.tb00165.x
G. de Rassenfosse, B. van Pottelsberghe de la Potterie, THE ROLE OF FEES IN PATENT SYSTEMS: THEORY AND EVIDENCE, Journal of Economic Surveys, vol. 27, no. 4, 2013, pp. 696–716. https://doi.org/10.1111/j.1467-6419.2011.00712.x
J. S. Sherkow, Inventive steps: the CRISPR patent dispute and scientific progress: The recent patent decisions about CRISPR tell us a lot about how advances in biology are actually made-and how they are not, EMBO Reports, vol. 18, no. 7, 2017, pp. 1047–1051. https://doi.org/10.15252/embr.201744418
J. Abbasi, COVID-19 and mRNA Vaccines-First Large Test for a New Approach, JAMA : the Journal of the American Medical Association, vol. 324, no. 12, 2020, pp.1125–1127. https://doi.org/10.1001/jama.2020.16866
K. Lee, M. Kim, Y. Seo, H. Lee, Development of mRNA vaccines and their prophylactic and therapeutic applications, Nano Research, vol. 11, no. 10, 2018, pp. 5173–5192. https://doi.org/10.1007/s12274-018-2095-8
S. Yamanaka, Ekiden to iPS Cells, Nature Medicine, vol. 15, no. 10, 2009, pp. 1145–1148. https://doi.org/10.1038/nm1009-1145
A. Sadick, The dispute of the patent term extension in Australia, Journal of Intellectual Property Law & Practice, vol. 14, no. 9, 2019, pp. 699-715. https://doi.org/10.1093/jiplp/jpz081
J. A. DiMasi, New drug development in the United States from 1963 to 1999, Clinical Pharmacology and Therapeutics, vol. 69, no. 5, 2001, pp. 286-296. https://doi.org/10.1067/mcp.2001.115132
GM. Dutfield, Healthcare Innovation and Patent Law’s ‘Pharmaceutical Privilege’: Is there a pharmaceutical privilege? And if so, should we remove it? Health Economics, Policy and Law, vol. 12, no. 4, pp. 453-470.
H. V. J. Moir, Exploring Evergreening: Insights from Two Medicines: Exploring Evergreening, Australian Economic Review, vol. 49, no. 4, 2016, pp. 413-431. https://doi.org/10.1111/1467-8462.12171
R. F. Beall, J. W. Nickerson, W. A. Kaplan, A. Attaran, H. Fehrenbach, Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products, PloS One, vol. 11, no. 2, 2016, e0148939-e0148939. https://doi.org/10.1371/journal.pone.0148939
A patent waiver on COVID vaccines is right and fair, Nature (London), vol. 593, no. 7860, 2021, pp. 478–478. https://doi.org/10.1038/d41586-021-01242-1
J. Barnes-Weise, A. Santos Rutschman, R. Adler, Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem, Journal of Epidemiology and Community Health (1979), vol. 76, no. 4, 2022, pp. 317–318. https://doi.org/10.1136/jech-2021-218409
G. Iacobucci, Covid-19: How will a waiver on vaccine patents affect global supply, BMJ (Online), vol. 373, 2021, n1182-n1182. https://doi.org/10.1136/bmj.n1182
J. Milstien, L. Belgharbi, Regulatory pathways for vaccines for developing countries, Bulletin of the World Health Organization, vol. 82, no. 2, 2004, pp.128-133. https://doi.org/10.1590/S0042-96862004000200010
L. Du, M. Wang, V. L. Raposo, International Efforts and Next Steps to Advance COVID-19 Vaccines Research and Production in Low- and Middle-Income Countries, Vaccines (Basel), vol. 10, no. 1, 2021, pp. 42. https://doi.org/10.3390/vaccines10010042
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
